Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients

Darrell Crawford, Gregory J Dore, William Sievert, Wendy Cheng, Martin D Weltman, Geoffrey McCaughan, William Rawlinson, Phillipa Marks, Motoko Yoshihara, Bishoy Rizkalla, Stuart K Roberts

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


BACKGROUND: On-treatment HCV viral load during early therapy with pegylated interferon (PEG-IFN) and ribavirin is highly predictive of sustained virological response (SVR). We sought to provide further refinement of this prediction through an extensive evaluation of the effect of HCV viral loads at weeks 4, 8 and 12 on SVR, including analysis by liver disease stage grouping. METHODS: A total of 309 patients with genotype 1 chronic HCV and recent liver biopsy enrolled in the CHARIOT study received 180 mug of PEG-IFN-alpha2a weekly with 1,000/1,200 mg of ribavirin daily. The probability of an SVR was estimated using baseline METAVIR fibrosis stage and HCV viral loads at weeks 4, 8 and 12. RESULTS: HCV RNA was undetectable in 27.5 , 50.3 and 62.6 of patients at weeks 4, 8 and 12, respectively. SVR was 80.0 , 76.8 and 72.4 among patients with undetectable HCV RNA at weeks 4, 8 and 12, respectively. SVR decreased in a progressive fashion with increasing HCV viral loads at each early time point, but was similar for patients with HCV viral load 1,000 IU/ml, and all HCV viral load categories at weeks 8 and 12. CONCLUSIONS: A combination of baseline fibrosis stage and on-treatment HCV viral load at early time points provides improved estimates for treatment response in patients with chronic HCV genotype 1.
Original languageEnglish
Pages (from-to)849 - 854
Number of pages6
JournalAntiviral Therapy
Issue number5
Publication statusPublished - 2012

Cite this